Published research on Mebendazole
5 peer-reviewed publications on Mebendazole in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Clinical trial
A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas
In 10 children and young adults with high-grade glioma, mebendazole combined with bevacizumab and irinotecan produced no dose-limiting toxicities, an overall response rate of 33%, and mean progression-free and overall survival of 4.7 and 11.4 months.
- Case report
In a 74-year-old man with chemotherapy-refractory metastatic colon cancer treated with mebendazole at the standard anthelmintic dose, CT showed near-complete remission of lung and lymph node metastases and partial remission of liver metastases, with a transient rise in liver enzymes.
- Review
The review reported that in vitro studies showed mebendazole inhibited tubulin polymerization, angiogenesis and pro-survival pathways, and that in vivo studies showed reduced tumour growth and metastatic spread, while clinical anticancer activity remained to be confirmed.
- Review
Repurposing Drugs in Oncology (ReDO): mebendazole as an anti-cancer agent
The authors summarised preclinical evidence of anticancer activity of mebendazole across several cancer types and two human case reports, and proposed that further exploration of mebendazole as an anticancer therapeutic was warranted.
- In vivo
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Mebendazole was cytotoxic to glioblastoma cell lines at sub-micromolar concentrations, disrupted microtubule formation, and extended mean survival by up to 63% in syngeneic and xenograft orthotopic mouse glioma models.
Mebendazole in the catalog (specifications, pack sizes, Certificate of Analysis)